HOOKIPA PharmaHOOK 50 EBIT per Share is $-4.47 as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 50/100 and a GF Value™ of $2.77 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,180 Biotechnology companies, HOOKIPA Pharma ranks better than 85.34% on this metric.
HOOKIPA Pharma's EBIT per Share for the
three
months ended in Jun. 2025 was $-0.14.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 was $-4.47.
During the past 3 years, the average EBIT per Share Growth Rate was 48.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 32.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for HOOKIPA Pharma's EBIT per Share or its related term are showing as below:
HOOK'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -34.3 Med: 24.3 Max: 48.6
Current: 48.6
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of HOOKIPA Pharma was 48.60% per year. The lowest was -34.30% per year. And the median was 24.30% per year.
HOOK's 3-Year EBIT Growth Rate is ranked better than 85.34% of 1180
companies
in the Biotechnology industry
Industry Median: 15.55
vs HOOK: 48.60
HOOKIPA Pharma's EBIT for the
three
months ended in Jun. 2025 was $-1.79 Mil.
HOOKIPA Pharma (OTCPK:HOOK) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
HOOKIPA Pharma EBIT per Share Related Terms
HOOKIPA Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma (HOOK) has a EBIT per Share of $-4.47 as of Jun. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on HOOKIPA Pharma and its competitors. According to the industry distribution chart, HOOKIPA Pharma ranks #173 out of 1180 companies in the Biotechnology industry, placing it in the top 14.7%.
Is HOOKIPA Pharma's EBIT per Share too high?
HOOKIPA Pharma's current EBIT per Share is $-4.47. Based on the distribution chart, HOOKIPA Pharma ranks #173 out of 1180 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HOOKIPA Pharma has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's EBIT per Share compare to COCP and LNAI?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #173 out of 1180 companies for EBIT per Share. This places HOOKIPA Pharma in the top 15% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,180 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on HOOKIPA Pharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOOKIPA Pharma's current EBIT per Share is $-4.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.77, compared to a current price of $1.15 — trading 58.5% below its estimated fair value. The current EBIT per Share is $-4.47. HOOKIPA Pharma's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current EBIT per Share is $-4.47 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOOKIPA Pharma (HOOK) Overvalued in 2026?
Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued.
The current stock price of $1.15 is trading 58.5% below its estimated GF Value™ of $2.77.
GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.
Key valuation signals for HOOK:
EBIT per Share: $-4.47
GF Value™: $2.77 vs. price of $1.15 (58.5% below fair value)
No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score
Get the complete analysis for HOOK
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
